Hepatitis C virus (HCV) polymerase is an essential enzyme for HCV replication and has multiple inhibitor binding sites making it a major target for antiviral intervention. It is apparent that no single drug can inhibit HCV replication in humans. Hence, combinations of nucleoside analogues β-D-2'-C-methylcytidine (2'-C-MeC; NM-107) or β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (2'-F-C-MeC; PSI-6130) with interferon-α2b (IFN-α2b) or triple combination with ribavirin (RBV) were evaluated.
Methods:
Huh-7 cells containing the self-replicating subgenomic HCV replicon (Clone B) were used for drug combination studies. After drug treatment for 5 days, total cellular RNA was then extracted and both ribosomal RNA and HCV replicon RNA were amplified in a single-step multiplex real-time PCR assay. Drug interaction analyses were performed using the CalcuSyn program.
Results:
Double combinations of 2'-C-MeC or 2'-F-C-MeC with IFN-α2b at all ratios tested had weighted average combination index (CIwt) values <1 indicating synergistic inhibition of HCV replication in the replicon system. For the triple combinations of IFN-α2b plus RBV with either 2'-C-MeC or 2'-F-C-MeC, the CIwt values at 1:1:1 ratio tested were 0.5 and 0.8, respectively, indicating synergistic antiviral effects. No apparent cytotoxicity effects were observed with any of the combinations tested.
Conclusion:
These promising in vitro data warrant clinical investigation of the nucleosides analogues such as 2'-C-MeC or 2'-F-C-MeC in their prodrug forms, together with IFN-α2b and RBV, for successful treatment of HCV infections.
References
1.
AbergelAHezodeCLeroyV. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: A multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. J Viral Hepat2006; 13: 811–820.
2.
BronowickiJPOuzanDAsselahT. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2a plus ribavirin. Gastroenterology2006; 131: 1040–1048.
3.
CarrollSSOlsenDB. Nucleoside analogue inhibitors of hepatitis C virus replication. Infect Disord Drug Targets2006; 6: 17–29.
4.
PierraCBenzariaSAmadorA. NM 283, an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. Nucleosides Nucleotides Nucleic Acids2005; 24: 767–770.
5.
PierraCAmadorABenzariaS. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J Med Chem2006; 49: 6614–6620.
6.
ToniuttoPFabrisCBitettoDFornasiereERapettiRPirisiM. Valopicitabine dihydrochloride: A specificpolymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs2007; 8: 150–158.
7.
StuyverLJMcBrayerTRTharnishPM. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine: A specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother2006; 17: 79–87.
8.
MurakamiEBaoHRameshM. Mechanism of activation of beta-D-2′-deoxy-2′-fluoro-2′-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother2007; 51: 503–509.
9.
ReddyRRodriguez-TorresMGaneE. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV fenotype 1 infection who have failed prior interferon therapy. Hepatology2007; 46Suppl 1: 862A.
10.
McHutchisonJGReddyRRodriguez-TorresM. Potent antiviral activity of the nucleoside HCV inhibitor, R7128, in prior IFN non-responders. Hep DART Frontiers in Drug Development for Viral Hepatitis. 9–13 December 2007, Lahaina, Hawaii, USA. Abstract 61.
11.
SchinaziRFBassitLMateuGMcBrayerTGrakouiA. Development and validation of a robust acute hepatitis C virus infectious system for novel drug evaluation in vitro. 14th International Symposium on Hepatitis C Virus & Related Viruses. 9–13 September 2007, Glasgow, Scotland, UK. Abstract P–275.
12.
CoelmontLPaeshuyseJWindischMPDe ClercqEBartenschlagerRNeytsJ. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother2006; 50: 3444–3446.
13.
NeumannAULamNPDahariH. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science1998; 282: 103–107.
14.
GuoJTZhuQSeegerC. Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons. J Virol2003; 77: 10769–10779.
15.
EldrupABAllersonCRBennettCF. Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem2004; 47: 2283–2295.
16.
ClarkJLHolleckerLMasonJC. Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J Med Chem2005; 48: 5504–5508.
17.
BlightKJKolykhalovAARiceCM. Efficient initiation of HCV RNA ' replication in cell culture. Science2000; 290: 1972–1974.
18.
StuyverLJWhitakerTMcBrayerTR. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother2003; 47: 244–254.
19.
ChouTCTalalayP. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul1984; 22: 27–55.
20.
Belen'kiiMSSchinaziRF. Multiple drug effect analysis with confidence interval. Antiviral Res1994; 25: 1–11.
21.
ChouTC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev2006; 58: 621–681.
22.
McHutchisonJGGordonSCSchiffER. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med1998; 339: 1485–1492.
23.
ZhangYJamaluddinMWangS. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol2003; 77: 5933–5947.
24.
FeldJJHoofnagleJH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature2005; 436: 967–972.
25.
LanfordREGuerraBLeeH. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol2003; 77: 1092–1104.
26.
TanabeYSakamotoNEnomotoN. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis2004; 189: 1129–1139.
Hernandez-SantiagoBIBassitLGrierJSchinaziRF. Anti-HCV activity and cellular pharmacology of 2′-methylcytidine alone and in combination with non-toxic concentrations of ribavirin in the HCV replicon system. Antivir Ther2007; 12: S28.
30.
DieterishDLawitzENguyenT. Early clearance of HCV RNA with valopicitabine (NM283) plus PEG-Interferon in treatment-naïve patients with HCV-1 infection: First results from a phase IIb trial. J Hepatol200644Suppl 2: S271–S272.
31.
StauberREStadlbauerV. Novel approaches for therapy of chronic hepatitis C. J Clin Virol2006; 36: 87–94.
